Article
B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
Oncogene - 1 Jan 2022
Lu Youwei, Wu Fengying, Cao Qiuyi, Sun Yu, Huang Moli, Xiao Jing, Zhou Bin, Zhang Liang
Abstract excerpt
PD-1/PD-L1 inhibitors have shown clinical benefit in lung adenocarcinoma (LUAD). However, the immunotherapy strategy is less effective in patients with EGFR-activating mutations (EGFR MT). Studies showed that besides low expression of PD-L1, the absence of TILs and distinct expression profile of immune checkpoint molecules might be associated with low response of the patient subset. In this study, we first...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.